SEARCH

SEARCH BY CITATION

References

  • Abraham, R.S., Geyer, S.M., Price-Troska, T.L., Allmer, C., Kyle, R.A., Gertz, M.A. & Fonseca, R. (2003) Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL). Blood, 101, 38013808.
  • Adamski-Werner, S.L., Palaninathan, S.K., Sacchettini, J.C. & Kelly, J.W. (2004) Diflunisal analogues stabilize the native state of transthyretin. Potent inhibition of amyloidogenesis. Journal of Medical Chemistry, 47, 355374.
  • Attal, M., Harousseau, J.L., Facon, T., Guilhot, F., Doyen, C., Fuzibet, J.G., Monconduit, M., Hulin, C., Caillot, D., Bouabdallah, R., Voillat, L., Sotto, J.J., Grosbois, B. & Bataille, R. (2003) Single versus double autologous stem-cell transplantation for multiple myeloma. New England Journal of Medicine, 349, 24952502.
  • Benson, M.D. (1986) Treatment of AL amyloidosis with melphalan, prednisone, and colchicine. Arthritis Rheumatism, 29, 683687.
  • Boruchov, A., Zhou, A., Olshen, A., Rankin, C., Bonvini, E., Koenig, S., Fleisher, M., McKenzie, S., Maslak, P., Jhanwar, S., Young, J., Nimer, S. & Comenzo, R. (2007) CD32B in multiple myeloma and systemic AL-amyloidosis. Haematologica, 92 (Suppl. 109), 225. (abstract).
  • Buxbaum, J.N., Hurley, M.E., Chuba, J. & Spiro, T. (1979) Amyloidosis of the AL type. Clinical, morphologic and biochemical aspects of the response to therapy with alkylating agents and prednisone. American Journal of Medicine, 67, 867878.
  • Cohen, A.S., Rubinow, A., Anderson, J.J., Skinner, M., Mason, J.H., Libbey, C. & Kayne, H. (1987) Survival of patients with primary (AL) amyloidosis. Colchicine-treated cases from 1976 to 1983 compared with cases seen in previous years (1961 to 1973). American Journal of Medicine, 82, 11821190.
  • Cohen, A.D., Zhou, P., Reich, L., Hassoun, H., Teruya-Feldstein, J., Filippa, D.A., Fleisher, M., Nimer, S.D. & Comenzo, R.L. (2005) Adjuvant dexamethasone (D) {+/-} thalidomide (T) improves hematologic and organ responses after risk-adapted high-dose melphalan with autologous stem cell transplant (SCT) for patients with systemic AL amyloidosis (AL). Blood, 106, 1163. (abstract).
  • Comenzo, R.L., Vosburgh, E., Simms, R.W., Bergethon, P., Sarnacki, D., Finn, K., Dubrey, S., Faller, D.V., Wright, D.G., Falk, R.H. & Skinner, M. (1996) Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients. Blood, 88, 28012806.
  • Comenzo, R.L., Vosburgh, E., Falk, R.H., Sanchorawala, V., Reisinger, J., Dubrey, S., Dember, L.M., Berk, J.L., Akpek, G., LaValley, M., O’Hara, C., Arkin, C.F., Wright, D.G. & Skinner, M. (1998) Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients. Blood, 91, 36623670.
  • Comenzo, R.L., Zhang, Y., Martinez, C., Osman, K. & Herrera, G.A. (2001) The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V(L) germ line gene use and clonal plasma cell burden. Blood, 98, 714720.
  • Dember, L.M., Hawkins, P.N., Hazenberg, B.P.C., Gorevic, P.D., Merlini, G., Butrimiene, I., Livneh, A., Lesnyak, O., Puechal, X., Lachmann, H.J., Obici, L., Balshaw, R., Garceau, D., Hauck, W., Skinner, M. & the Eprodisate for AA Amyloidosis Trials Group. (2007) Eprodisate for the treatment of renal disease in AA amyloidosis. New England Journal of Medicine, 356, 23492360.
  • Desikan, K.R., Dhodapkar, M.V., Hough, A., Waldron, T., Jagannath, S., Siegel, D., Barlogie, B. & Tricot, G. (1997) Incidence and impact of light chain associated (AL) amyloidosis on the prognosis of patients with multiple myeloma treated with autologous transplantation. Leukemia & Lymphoma, 27, 315319.
  • Dhodapkar, M.V., Hussein, M.A., Rasmussen, E., Solomon, A., Larson, R.A., Crowley, J.J. & Barlogie, B. (2004) Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628. Blood, 104, 35203526.
  • Dispenzieri, A., Lacy, M.Q., Kyle, R.A., Therneau, T.M., Larson, D.R., Rajkumar, S.V., Fonseca, R., Greipp, P.R., Witzig, T.E., Lust, J.A. & Gertz, M.A. (2001) Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. Journal of Clinical Oncology, 19, 33503356.
  • Dispenzieri, A., Lacy, M.Q., Rajkumar, S.V., Geyer, S.M., Witzig, T.E., Fonseca, R., Lust, J.A., Greipp, P.R., Kyle, R.A. & Gertz, M.A. (2003) Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis. Amyloid, 10, 257261.
  • Dispenzieri, A., Lacy, M.Q., Geyer, S.M., Greipp, P.R., Witzig, T.E., Lust, J.A., Zeldenrust, S.R., Rajkumar, S.V., Kyle, R.A., Fonseca, R. & Gertz, M.A. (2004a) Low dose single agent thalidomide is tolerated in patients with primary systemic amyloidosis, but responses are limited. Blood, 104, 4920. (abstract).
  • Dispenzieri, A., Kyle, R.A., Lacy, M.Q., Therneau, T.M., Larson, D.R., Plevak, M.F., Rajkumar, S.V., Fonseca, R., Greipp, P.R., Witzig, T.E., Lust, J.A., Zeldenrust, S.R., Snow, D.S., Hayman, S.R., Litzow, M.R., Gastineau, D.A., Tefferi, A., Inwards, D.J., Micallef, I.N., Ansell, S.M., Porrata, L.F., Elliott, M.A. & Gertz, M.A. (2004b) Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood, 103, 39603963.
  • Dispenzieri, A., Lacy, M.Q., Katzmann, J.A., Rajkumar, S.V., Abraham, R.S., Hayman, S.R., Kumar, S.K., Clark, R., Kyle, R.A., Litzow, M.R., Inwards, D.J., Ansell, S.M., Micallef, I.M., Porrata, L.F., Elliott, M.A., Johnston, P.B., Greipp, P.R., Witzig, T.E., Zeldenrust, S.R., Russell, S.J., Gastineau, D. & Gertz, M.A. (2006) Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood, 107, 33783383.
  • Dispenzieri, A., Lacy, M.Q., Zeldenrust, S.R., Hayman, S.R., Kumar, S.K., Geyer, S.M., Lust, J.A., Allred, J.B., Witzig, T.E., Rajkumar, S.V., Greipp, P.R., Russell, S.J., Kabat, B. & Gertz, M.A. (2007) The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood, 109, 465470.
  • Fonseca, R., Ahmann, G.J., Jalal, S.M., Dewald, G.W., Larson, D.R., Therneau, T.M., Gertz, M.A., Kyle, R.A. & Greipp, P.R. (1998) Chromosomal abnormalities in systemic amyloidosis. British Journal of Haematology, 103, 704710.
  • Gertz, M.A. & Kyle, R.A. (1986) Response of primary hepatic amyloidosis to melphalan and prednisone: a case report and review of the literature. Mayo Clinic Proceedings, 61, 218223.
  • Gertz, M.A., Greipp, P.R. & Kyle, R.A. (1991) Classification of amyloidosis by the detection of clonal excess of plasma cells in the bone marrow. Journal of Laboratory and Clinical Medicine, 118, 3339.
  • Gertz, M.A., Lacy, M.Q., Lust, J.A., Greipp, P.R., Witzig, T.E. & Kyle, R.A. (1999) Prospective randomized trial of melphalan and prednisone versus vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of primary systemic amyloidosis. Journal of Clinical Oncology, 17, 262267.
  • Gertz, M.A., Lacy, M.Q., Dispenzieri, A., Ansell, S.M., Elliott, M.A., Gastineau, D.A., Inwards, D.J., Micallef, I.N., Porrata, L.F., Tefferi, A. & Litzow, M.R. (2004) Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate. Bone Marrow Transplantation, 34, 10251031.
  • Gertz, M.A., Comenzo, R., Falk, R.H., Fermand, J.P., Hazenberg, B.P., Hawkins, P.N., Merlini, G., Moreau, P., Ronco, P., Sanchorawala, V., Sezer, O., Solomon, A. & Grateau, G. (2005a) Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis. American Journal of Hematology, 79, 319328.
  • Gertz, M.A., Lacy, M.Q., Dispenzieri, A., Greipp, P.R., Litzow, M.R., Henderson, K.J., Van Wier, S.A., Ahmann, G.J. & Fonseca, R. (2005b) Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and −17p13 in myeloma patients treated with high-dose therapy. Blood, 106, 28372840.
  • Gertz, M.A., Lacy, M.Q., Dispenzieri, A. & Hayman, S.R. (2005c) Amyloidosis. Best Practice & Research. Clinical Haematology, 18, 709727.
  • Gillmore, J.D., Davies, J., Iqbal, A., Madhoo, S., Russell, N.H. & Hawkins, P.N. (1998) Allogeneic bone marrow transplantation for systemic AL amyloidosis. British Journal of Haematology, 100, 226228.
  • Gillmore, J.D., Goodman, H.J., Lachmann, H.J., Offer, M., Wechalekar, A.D., Joshi, J., Pepys, M.B. & Hawkins, P.N. (2006) Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis. Blood, 107, 12271229.
  • Goodman, H.J.B., Lachmann, H.J., Bradwell, A.R. & Hawkins, P.N. (2004) Intermediate dose intravenous melphalan and dexamethasone treatment in 144 patients with systemic al amyloidosis. ASH Annual Meeting Abstracts, 104, 755.
  • Goodman, H., Wechalekar, A., Lachmann, H., Bradwell, A. & Hawkins, P. (2005) Clonal diseaes response and clinical outcome in 229 patients with AL amyloidosis treated with VAD-like chemotherapy. Haematologica/The Hematology Journal, 90, 201. (abstracts).
  • Goodman, H.J., Gillmore, J.D., Lachmann, H.J., Wechalekar, A.D., Bradwell, A.R. & Hawkins, P.N. (2006) Outcome of autologous stem cell transplantation for AL amyloidosis in the UK. British Journal of Haematology, 134, 417425.
  • Guidelines Working Group of UK Myeloma Forum, British Committee for Standards in Haematology, British Society for Haematology. (2004) Guidelines on the diagnosis and management of AL amyloidosis. British Journal of Haematology, 125, 681700.
  • Harris, D.L., King, E., Ramsland, P.A. & Edmundson, A.B. (2000) Binding of nascent collagen by amyloidogenic light chains and amyloid fibrillogenesis in monolayers of human fibrocytes. Journal of Molecular Recognition, 13, 198212.
  • Harrison, C.J., Mazzullo, H., Ross, F.M., Cheung, K.L., Gerrard, G., Harewood, L., Mehta, A., Lachmann, H.J., Hawkins, P.N. & Orchard, K.H. (2002) Translocations of 14q32 and deletions of 13q14 are common chromosomal abnormalities in systemic amyloidosis. British Journal of Haematology, 117, 427435.
  • Hawkins, P.N., Myers, M.J., Epenetos, A.A., Caspi, D. & Pepys, M.B. (1988) Specific localization and imaging of amyloid deposits in vivo using 123I-labeled serum amyloid P component. The Journal of Experimental Medicine, 167, 903913.
  • Hawkins, P.N., Lavender, J.P. & Pepys, M.B. (1990) Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. New England Journal of Medicine, 323, 508513.
  • Hayman, S.R., Bailey, R.J., Jalal, S.M., Ahmann, G.J., Dispenzieri, A., Gertz, M.A., Greipp, P.R., Kyle, R.A., Lacy, M.Q., Rajkumar, S.V., Witzig, T.E., Lust, J.A. & Fonseca, R. (2001) Translocations involving the immunoglobulin heavy-chain locus are possible early genetic events in patients with primary systemic amyloidosis. Blood, 98, 22662268.
  • Imamura, T., Ogata, M., Kohno, K., Tomo, T., Ohtsuka, E., Kikuchi, H. & Kadota, J. (2006) Successful reduced intensity allogeneic stem cell transplantation for systemic AL amyloidosis. American Journal of Hematology, 81, 281283.
  • Jaccard, A., Moreau, P., Leblond, V., Leleu, X., Benboubker, L., Hermine, O., Recher, C., Malphette, M., Lioure, B., Royer, B., Grosbois, B., Jaubert, J., Preux, P.M., Cogne, M. & Fermand, J.P. (2005) Autologous stem cell transplantation (ASCT) versus oral melphalan and high-dose dexamethasone in patients with AL (primary) amyloidosis: results of the French Multicentric Randomized Trial (MAG and IFM Intergroup). Blood, 106, 421. (abstract).
  • Kawai, Y., Kinoshita, K., Arai, H., Kuwata, A., Fukuoka, Y., Yamaoka, M., Imamura, S., Tsutani, H. & Ueda, T. (2004) Reduced intensity allogeneic stem cell transplantation for systemic primary amyloidosis refractory to high-dose melphalan. European Journal of Haematology, 72, 448450.
  • Kisilevsky, R. (2000a) Review: amyloidogenesis-unquestioned answers and unanswered questions. Journal of Structural Biology, 130, 99108.
  • Kisilevsky, R. (2000b) The relation of proteoglycans, serum amyloid P and apo E to amyloidosis current status, 2000. Amyloid, 7, 2325.
  • Kisilevsky, R. & Szarek, W.A. (2002) Novel glycosaminoglycan precursors as anti-amyloid agents part II. Journal of Molecular Neuroscience, 19, 4550.
  • Kisilevsky, R., Ancsin, J.B., Szarek, W.A. & Petanceska, S. (2007) Heparan sulfate as a therapeutic target in amyloidogenesis: prospects and possible complications. Amyloid, 14, 2132.
  • Kyle, R.A. & Gertz, M.A. (1995) Primary systemic amyloidosis: clinical laboratory features in 474 cases. Seminars in Hematology, 32, 4559.
  • Kyle, R.A., Wagoner, R.D. & Holley, K.E. (1982) Primary systemic amyloidosis: resolution of the nephrotic syndrome with melphalan and prednisone. Archives of Internal Medicine, 142, 14451447.
  • Kyle, R.A., Greipp, P.R., Garton, J.P. & Gertz, M.A. (1985) Primary systemic amyloidosis. Comparison of melphalan/prednisone versus colchicine. American Journal of Medicine, 79, 708716.
  • Kyle, R.A., Linos, A., Beard, C.M., Linke, R.P., Gertz, M.A., O’Fallon, W.M. & Kurland, L.T. (1992) Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood, 79, 18171822.
  • Kyle, R.A., Gertz, M.A., Greipp, P.R., Witzig, T.E., Lust, J.A., Lacy, M.Q. & Therneau, T.M. (1997) A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. New England Journal of Medicine, 336, 12021207.
  • Kyle, R.A., Gertz, M.A., Greipp, P.R., Witzig, T.E., Lust, J.A., Lacy, M.Q. & Therneau, T.M. (1999) Long-term survival (10 years or more) in 30 patients with primary amyloidosis. Blood, 93, 10621066.
  • Lachmann, H.J., Gallimore, R., Gillmore, J.D., Carr-Smith, H.D., Bradwell, A.R., Pepys, M.B. & Hawkins, P.N. (2003) Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. British Journal of Haematology, 122, 7884.
  • Majolino, I., Marceno, R., Pecoraro, G., Scime, R., Vasta, S., Liberti, G., Rizzo, A., Indovina, A. & Caronia, F. (1993a) Autologous stem cell transplantation in amyloidosis AL. Bone Marrow Transplantation, 11, 85.
  • Majolino, I., Marceno, R., Pecoraro, G., Scime, R., Vasta, S., Liberti, G., Rizzo, A., Indovina, A. & Caronia, F. (1993b) High-dose therapy and autologous transplantation in amyloidosis-AL. Haematologica, 78, 6871.
  • Manochakian, R., Miller, K.C. & Chanan-Khan, A.A. (2007) Bortezomib in combination with pegylated liposomal doxorubicin for the treatment of multiple myeloma. Clinical Lymphoma & Myeloma, 7, 266271.
  • Mateos, M.V., Hernandez, J.M., Hernandez, M.T., Gutierrez, N.C., Palomera, L., Fuertes, M., Diaz-Mediavilla, J., Lahuerta, J.J., De La Rubia, J., Terol, M.J., Sureda, A., Bargay, J., Ribas, P., De Arriba, F., Alegre, A., Oriol, A., Carrera, D., Garcia-Larana, J., Garcia-Sanz, R., Blade, J., Prosper, F., Mateo, G., Esseltine, D.L., Van De Velde, H. & San Miguel, J.F. (2006) Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood, 108, 21652172.
  • Merlini, G. & Stone, M.J. (2006) Dangerous small B-cell clones. Blood, 108, 25202530.
  • Mollee, P.N., Wechalekar, A.D., Pereira, D.L., Franke, N., Reece, D., Chen, C. & Stewart, A.K. (2004) Autologous stem cell transplantation in primary systemic amyloidosis: the impact of selection criteria on outcome. Bone Marrow Transplantation, 33, 271277.
  • Moreau, P., Leblond, V., Bourquelot, P., Facon, T., Huynh, A., Caillot, D., Hermine, O., Attal, M., Hamidou, M., Nedellec, G., Ferrant, A., Audhuy, B., Bataille, R., Milpied, N. & Harousseau, J.L. (1998) Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients. British Journal of Haematology, 101, 766769.
  • Nelson, S.R., Lyon, M., Gallagher, J.T., Johnson, E.A. & Pepys, M.B. (1991) Isolation and characterization of the integral glycosaminoglycan constituents of human amyloid A and monoclonal light-chain amyloid fibrils. Biochemistry Journal, 275( Pt 1), 6773.
  • O’Nuallain, B., Hrncic, R., Wall, J.S., Weiss, D.T. & Solomon, A. (2006) Diagnostic and therapeutic potential of amyloid-reactive IgG antibodies contained in human sera. Journal of Immunology, 176, 70717078.
  • Offer, M., Wechalekar, A.D., Goodman, H.J.B., Gillmore, J.D., Lachmann, H.J., Bradwell, A.R. & Hawkins, P.N. (2005) Standard oral melphalan chemotherapy for al amyloidosis revisited using the serum free light chain assay. Blood, 106, 3495. (abstract).
  • Palladini, G., Anesi, E., Perfetti, V., Obici, L., Invernizzi, R., Balduini, C., Ascari, E. & Merlini, G. (2001) A modified high-dose dexamethasone regimen for primary systemic (AL) amyloidosis. British Journal of Haematology, 113, 10441046.
  • Palladini, G., Perfetti, V., Obici, L., Caccialanza, R., Semino, A., Adami, F., Cavallero, G., Rustichelli, R., Virga, G. & Merlini, G. (2004) Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood, 103, 29362938.
  • Palladini, G., Perfetti, V., Perlini, S., Obici, L., Lavatelli, F., Caccialanza, R., Invernizzi, R., Comotti, B. & Merlini, G. (2005) The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood, 105, 29492951.
  • Palladini, G., Lavatelli, F., Russo, P., Perlini, S., Perfetti, V., Bosoni, T., Obici, L., Bradwell, A.R., D’Eril, G.M., Fogari, R., Moratti, R. & Merlini, G. (2006) Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood, 107, 38543858.
  • Palladini, G., Russo, P., Nuvolone, M., Lavatelli, F., Perfetti, V., Obici, L. & Merlini, G. (2007) Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis. Blood, 110, 787788.
  • Palumbo, A., Ambrosini, M.T., Benevolo, G., Pregno, P., Pescosta, N., Callea, V., Cangialosi, C., Caravita, T., Morabito, F., Musto, P., Bringhen, S., Falco, P., Avonto, I., Cavallo, F. & Boccadoro, M. (2007) Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. Blood, 109, 27672772.
  • Pepys, M.B. (2006) Amyloidosis. Annual Review of Medicine, 57, 223241.
  • Pepys, M.B., Herbert, J., Hutchinson, W.L., Tennent, G.A., Lachmann, H.J., Gallimore, J.R., Lovat, L.B., Bartfai, T., Alanine, A., Hertel, C., Hoffmann, T., Jakob-Roetne, R., Norcross, R.D., Kemp, J.A., Yamamura, K., Suzuki, M., Taylor, G.W., Murray, S., Thompson, D., Purvis, A., Kolstoe, S., Wood, S.P. & Hawkins, P.N. (2002) Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature, 417, 254259.
  • Perfetti, V., Colli Vignarelli, M., Anesi, E., Garini, P., Quaglini, S., Ascari, E. & Merlini, G. (1999) The degrees of plasma cell clonality and marrow infiltration adversely influence the prognosis of AL amyloidosis patients. Haematologica, 84, 218221.
  • Perfetti, V., Coluccia, A.M., Intini, D., Malgeri, U., Vignarelli, M.C., Casarini, S., Merlini, G. & Neri, A. (2001) Translocation T(4;14)(p16.3;q32) is a recurrent genetic lesion in primary amyloidosis. American Journal of Pathology, 158, 15991603.
  • Perfetti, V., Siena, S., Palladini, G., Bregni, M., Di Nicola, M., Obici, L., Magni, M., Brunetti, L., Gianni, A.M. & Merlini, G. (2006) Long-term results of a risk-adapted approach to melphalan conditioning in autologous peripheral blood stem cell transplantation for primary (AL) amyloidosis. Haematologica, 91, 16351643.
  • Phillips, G.L., Meisenberg, B.R., Reece, D.E., Adams, V.R., Badros, A.Z., Brunner, J.L., Fenton, R.G., Filicko, J., Grosso, D.L., Hale, G.A., Howard, D.S., Johnson, V.P., Kniska, A., Marshall, K.W., Mookerjee, B., Nath, R., Rapoport, A.P., Sarkodee-Adoo, C., Takebe, N., Vesole, D.H., Wagner, J.L. & Flomenberg, N. (2004) Activity of single-agent melphalan 220-300 mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma. Bone Marrow Transplantation, 33, 781787.
  • Rajkumar, S.V., Gertz, M.A. & Kyle, R.A. (1998) Primary systemic amyloidosis with delayed progression to multiple myeloma. Cancer, 82, 15011505.
  • Rajkumar, S.V., Jacobus, S., Callander, N., Fonseca, R., Vesole, D. & Greipp, P. (2006) A randomized phase iii trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group. Blood, 108, 799. (abstract).
  • Reece, D., Sanchorawala, V., Hegenbart, U., Merlini, G., Palladini, G., Fermand, J., Vescio, R., Liu, X., Elsayed, Y. & Comenzo, R. (2007) Phase I/II study of bortezomib (B) in patients with systemic AL-amyloidosis (AL). Journal of Clinical Oncology, 25, 8050. (abstract).
  • Sanchorawala, V., Wright, D.G., Seldin, D.C., Falk, R.H., Berk, J.L., Dember, L.M., Finn, K.T. & Skinner, M. (2002) Low-dose continuous oral melphalan for the treatment of primary systemic (AL) amyloidosis. British Journal of Haematology, 117, 886889.
  • Sanchorawala, V., Wright, D.G., Seldin, D.C., Falk, R.H., Finn, K.T., Dember, L.M., Berk, J.L., Quillen, K., Anderson, J.J., Comenzo, R.L. & Skinner, M. (2004) High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial. Bone Marrow Transplantation, 33, 381388.
  • Sanchorawala, V., Seldin, D.C., Magnani, B., Skinner, M. & Wright, D.G. (2005) Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis. Bone Marrow Transplantation, 36, 597600.
  • Sanchorawala, V., Skinner, M., Quillen, K., Finn, K.T., Doros, G. & Seldin, D.C. (2007a) Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation. Blood, 110, 35613563.
  • Sanchorawala, V., Wright, D.G., Rosenzweig, M., Finn, K.T., Fennessey, S., Zeldis, J.B., Skinner, M. & Seldin, D.C. (2007b) Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood, 109, 492496.
  • Sanchorawala, V., Wright, D.G., Quillen, K., Finn, K.T., Dember, L.M., Berk, J.L., Doros, G., Fisher, C., Skinner, M. & Seldin, D.C. (2007c) Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosis. Bone Marrow Transplantation, 40, 607.
  • Schonland, S.O., Perz, J.B., Hundemer, M., Hegenbart, U., Kristen, A.V., Hund, E., Dengler, T.J., Beimler, J., Zeier, M., Singer, R., Linke, R.P., Ho, A.D. & Goldschmidt, H. (2005) Indications for high-dose chemotherapy with autologous stem cell support in patients with systemic amyloid light chain amyloidosis. Transplantation, 80, S160S163.
  • Schonland, S.O., Lokhorst, H., Buzyn, A., Leblond, V., Hegenbart, U., Bandini, G., Campbell, A., Carreras, E., Ferrant, A., Grommisch, L., Jacobs, P., Kroger, N., La Nasa, G., Russell, N., Zachee, P., Goldschmidt, H., Iacobelli, S., Niederwieser, D. & Gahrton, G. (2006) Allogeneic and syngeneic hematopoietic cell transplantation in patients with amyloid light-chain amyloidosis: a report from the European Group for Blood and Marrow Transplantation. Blood, 107, 25782584.
  • Schormann, N., Murrell, J.R., Liepnieks, J.J. & Benson, M.D. (1995) Tertiary structure of an amyloid immunoglobulin light chain protein: a proposed model for amyloid fibril formation. Proceedings of National Academy of Science of the United States of America, 92, 94909494.
  • Seldin, D.C., Choufani, E.B., Dember, L.M., Wiesman, J.F., Berk, J.L., Falk, R.H., O’Hara, C., Fennessey, S., Finn, K.T., Wright, D.G., Skinner, M. & Sanchorawala, V. (2003) Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis. Clinical Lymphoma, 3, 241246.
  • Seldin, D.C., Anderson, J.J., Sanchorawala, V., Malek, K., Wright, D.G., Quillen, K., Finn, K.T., Berk, J.L., Dember, L.M., Falk, R.H. & Skinner, M. (2004) Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation. Blood, 104, 18881893.
  • Seldin, D.C., Anderson, J.J., Skinner, M., Malek, K., Wright, D.G., Quillen, K., Finn, K., Oran, B. & Sanchorawala, V. (2006) Successful treatment of AL amyloidosis with high-dose melphalan and autologous stem cell transplantation in patients over age 65. Blood, 108, 39453947.
  • Skinner, M., Anderson, J., Simms, R., Falk, R., Wang, M., Libbey, C., Jones, L.A. & Cohen, A.S. (1996) Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only. American Journal of Medicine, 100, 290298.
  • Skinner, M., Sanchorawala, V., Seldin, D.C., Dember, L.M., Falk, R.H., Berk, J.L., Anderson, J.J., O’Hara, C., Finn, K.T., Libbey, C.A., Wiesman, J., Quillen, K., Swan, N. & Wright, D.G. (2004) High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Annals of Internal Medicine, 140, 8593.
  • Stewart, A.K. & Fonseca, R. (2005) Prognostic and therapeutic significance of myeloma genetics and gene expression profiling. Journal of Clinical Oncology, 23, 63396344.
  • Stewart, A.K., Bergsagel, P.L., Greipp, P.R., Dispenzieri, A., Gertz, M.A., Hayman, S.R., Kumar, S., Lacy, M.Q., Lust, J.A., Russell, S.J., Witzig, T.E., Zeldenrust, S.R., Dingli, D., Reeder, C.B., Roy, V., Kyle, R.A., Rajkumar, S.V. & Fonseca, R. (2007) A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia, 21, 529534.
  • Sviggum, H.P., Davis, M.D., Rajkumar, S.V. & Dispenzieri, A. (2006) Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma. Archives of Dermatology, 142, 12981302.
  • Tennent, G.A., Lovat, L.B. & Pepys, M.B. (1995) Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis. Proceedings of National Academy of Science of the United States of America, 92, 42994303.
  • Vesole, D.H., Perez, W.S., Reece, D.E., Akasheh, M., Horowitz, M.M. & Bredeson, C. (2003) High dose therapy with autologous hematopoietic stem cell transplantation (HSCT) for patients with primary systemic amyloidosis (AL): results from the Autologous Blood and Marrow Transplant Registry (ABMTR). Blood, 102, 118A. (abstract).
  • Wechalekar, A., Orchard, K., Lachmann, H., Ross, F., Hawkins, P. & Harrison, C. (2004) Impact of chromosomal abnormalities revealed by interphase FISH on survival in primary light chain amyloidosis. ASH Annual Meeting Abstracts, 104, 4875.
  • Wechalekar, A.D., Goodman, H.J.B., Gillmore, J.D., Lachmann, H.J., Offer, M., Bradwell, A.R. & Hawkins, P.N. (2005a) Clinical profile and treatment outcome in 92 patients with AL amyloidosis associated with IgM paraproteinaemia. Blood, 106, 3498. (abstract).
  • Wechalekar, A.D., Lachmann, H.J., Gillmore, J.D., Goodman, H.J.B., Offer, M. & Hawkins, P.N. (2005b) The role of renal transplantation in systemic AL amyloidosis. Blood, 106, 3497. (abstract).
  • Wechalekar, A., Gillmore, J., Lachmann, H., Offer, M. & Hawkins, P. (2006) Efficacy and safety of bortezomib in systemic AL amyloidosis - a preliminary report. Blood, 108, 129.
  • Wechalekar, A.D., Goodman, H.J., Lachmann, H.J., Offer, M., Hawkins, P.N. & Gillmore, J.D. (2007) Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood, 109, 457464.
  • Witzig, T., Timm, M., Larson, D., Therneau, T. & Greipp, P. (1999) Measurement of apoptosis and proliferation of bone marrow plasma cells in patients with plasma cell proliferative disorders. British Journal of Haematology, 104, 131137.